ANIK Anika Therapeutics, Inc.
Stock · NasdaqGS · United States · Healthcare · US0352551081
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Anika Therapeutics, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
14.55 USD
-24.73%
52-week range
9.01 – 22.88
Dividend yield—
Market cap194.9M
NowoTrade score
32 Grade A
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:53. Information, not advice.
Results
Next results
25 Feb 2027
in 109 days · 08:00 · estimate 0.19
Last results
0.29 vs 0.17 estimated
06 Nov 2026 · Beat +70.6%
Beat the estimate
6 of 12
4 missed · 1 in line · 2 beats in a row
Average surprise
+238.8%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 08:00 | 0.19 | — | — | Upcoming |
| 06 Nov 2026 07:00 | 0.17 | 0.29 | +70.6% | Beat |
| 29 Jul 2026 07:00 | 0.03 | 0.42 | +1,300.0% | Beat |
| 29 Apr 2026 07:00 | — | 0.27 | — | — |
| 26 Feb 2026 07:00 | 0.02 | 0.31 | +1,450.0% | Beat |
| 05 Nov 2025 07:00 | 0.02 | 0.04 | +100.0% | Beat |
| 30 Jul 2025 07:00 | -0.13 | -0.13 | 0.0% | In line |
| 09 May 2025 07:00 | 0.09 | -0.06 | -166.7% | Miss |
| 12 Mar 2025 16:00 | 0.09 | -0.03 | -133.3% | Miss |
| 31 Oct 2024 07:00 | 0.30 | -0.25 | -183.3% | Miss |
| 08 Aug 2024 16:00 | 0.20 | 0.17 | -12.8% | Miss |
| 08 May 2024 16:00 | 0.05 | 0.09 | +80.0% | Beat |
| 13 Mar 2024 16:00 | -0.23 | 0.05 | +122.1% | Beat |
| 02 Nov 2023 16:00 | -0.35 | — | +100.0% | — |
| 08 Aug 2023 16:00 | -0.32 | 0.06 | +118.6% | Beat |
| 09 May 2023 16:00 | -0.32 | -0.36 | -12.5% | Miss |
| 06 Mar 2023 16:00 | -0.22 | -0.21 | +3.1% | Beat |
| 08 Nov 2022 16:00 | -0.23 | -0.05 | +78.6% | Beat |
| 03 Aug 2022 16:00 | -0.21 | -0.12 | +41.9% | Beat |
| 05 May 2022 16:00 | -0.31 | -0.11 | +64.9% | Beat |
| 08 Mar 2022 16:00 | -0.21 | -0.23 | -8.0% | Miss |
| 04 Nov 2021 16:00 | 0.05 | 0.05 | +1.7% | Beat |
| 05 Aug 2021 16:00 | -0.03 | 0.09 | +435.0% | Beat |
| 06 May 2021 16:00 | 0.01 | 0.06 | +500.0% | Beat |
| 04 Mar 2021 16:00 | 0.11 | 0.12 | +9.1% | Beat |
| 04 Nov 2020 16:00 | 0.13 | 0.05 | -61.5% | Miss |
| 30 Jul 2020 16:00 | -0.14 | 0.09 | +164.3% | Beat |
| 07 May 2020 17:00 | 0.22 | 0.45 | +107.1% | Beat |
| 20 Feb 2020 16:00 | 0.42 | 0.43 | +3.2% | Beat |
| 24 Oct 2019 16:00 | 0.39 | 0.64 | +62.7% | Beat |
| 24 Jul 2019 16:00 | 0.40 | 0.67 | +69.1% | Beat |
| 02 May 2019 16:00 | 0.20 | 0.31 | +56.9% | Beat |
| 21 Feb 2019 16:00 | 0.32 | 0.54 | +68.8% | Beat |
| 24 Oct 2018 16:00 | 0.31 | 0.53 | +69.0% | Beat |
| 25 Jul 2018 16:00 | 0.29 | 0.68 | +131.8% | Beat |
| 02 May 2018 16:00 | 0.25 | -0.46 | -281.6% | Miss |
| 21 Feb 2018 16:00 | 0.44 | 0.38 | -14.3% | Miss |
| 25 Oct 2017 16:00 | 0.42 | 0.46 | +9.5% | Beat |
| 26 Jul 2017 16:00 | 0.44 | 0.76 | +71.5% | Beat |
| 03 May 2017 16:00 | 0.38 | 0.37 | -1.9% | Miss |
| 15 Feb 2017 16:00 | 0.53 | 0.54 | +2.5% | Beat |
| 26 Oct 2016 16:00 | 0.47 | 0.59 | +24.7% | Beat |
| 27 Jul 2016 16:00 | 0.44 | 0.57 | +30.7% | Beat |
| 27 Apr 2016 16:00 | 0.27 | 0.45 | +64.0% | Beat |
| 24 Feb 2016 16:00 | 0.59 | 0.72 | +22.6% | Beat |
| 28 Oct 2015 16:00 | 0.35 | 0.55 | +59.4% | Beat |
| 29 Jul 2015 16:00 | 0.34 | 0.51 | +50.0% | Beat |
| 28 Apr 2015 16:00 | 0.21 | 0.23 | +9.5% | Beat |
| 25 Feb 2015 16:00 | 0.43 | 0.51 | +18.6% | Beat |
| 29 Oct 2014 16:00 | 0.33 | 0.40 | +21.2% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 112.8M | -5.9% | -10.9M | -9.6% | -0.76 | +80.2% | 4.4M |
| 2024 | 119.9M | -0.7% | -56.4M | -47.0% | -3.83 | +32.1% | -2.9M |
| 2023 | 120.8M | +6.1% | -82.7M | -68.4% | -5.64 | -452.9% | -7.2M |
| 2022 | 113.8M | — | -14.9M | -13.1% | -1.02 | — | -3.1M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 06 Nov 2026 | 17.87 | 17.88 | 13.90 | 14.55 | -24.73% | 294,000 | |
| 05 Nov 2026 | 20.57 | 20.61 | 19.07 | 19.33 | -5.25% | 113,200 | |
| 04 Nov 2026 | 19.88 | 20.65 | 19.88 | 20.40 | +4.88% | 95,300 | |
| 03 Nov 2026 | 19.53 | 21.55 | 19.06 | 19.45 | +0.21% | 95,600 | |
| 02 Nov 2026 | 21.04 | 21.09 | 19.36 | 19.41 | -7.35% | 95,300 | |
| 30 Oct 2026 | 21.80 | 21.80 | 20.81 | 20.95 | -3.85% | 66,700 | |
| 29 Oct 2026 | 21.56 | 21.85 | 21.36 | 21.79 | +1.11% | 121,800 | |
| 28 Oct 2026 | 21.15 | 21.63 | 21.08 | 21.55 | +0.94% | 97,800 | |
| 27 Oct 2026 | 21.25 | 21.71 | 21.04 | 21.35 | +0.38% | 82,900 | |
| 26 Oct 2026 | 21.48 | 21.55 | 20.96 | 21.27 | -0.70% | 96,200 | |
| 23 Oct 2026 | 20.87 | 21.45 | 20.60 | 21.42 | +1.56% | 59,200 | |
| 22 Oct 2026 | 20.38 | 21.09 | 20.11 | 21.09 | +2.38% | 61,400 | |
| 21 Oct 2026 | 20.48 | 20.61 | 20.22 | 20.60 | +0.78% | 51,300 | |
| 20 Oct 2026 | 20.22 | 20.63 | 20.11 | 20.44 | +1.09% | 363,000 | |
| 19 Oct 2026 | 19.94 | 20.53 | 19.87 | 20.22 | +1.20% | 66,500 | |
| 16 Oct 2026 | 20.73 | 20.75 | 19.84 | 19.98 | -3.43% | 81,900 | |
| 15 Oct 2026 | 20.41 | 20.91 | 20.31 | 20.69 | +2.17% | 84,800 | |
| 14 Oct 2026 | 20.34 | 20.61 | 20.12 | 20.25 | -1.36% | 93,500 | |
| 13 Oct 2026 | 20.47 | 20.77 | 20.00 | 20.53 | +0.29% | 96,200 | |
| 12 Oct 2026 | 19.53 | 20.69 | 19.33 | 20.47 | +4.55% | 152,600 | |
| 09 Oct 2026 | 19.24 | 19.95 | 19.24 | 19.58 | +1.82% | 88,600 | |
| 08 Oct 2026 | 19.39 | 19.39 | 18.90 | 19.23 | -1.54% | 126,200 | |
| 07 Oct 2026 | 19.01 | 19.63 | 18.11 | 19.53 | +2.14% | 182,700 | |
| 06 Oct 2026 | 19.73 | 19.80 | 19.05 | 19.12 | -3.09% | 64,700 | |
| 05 Oct 2026 | 19.18 | 19.88 | 19.07 | 19.73 | +3.30% | 122,300 |
Page 1 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Anika Therapeutics Inc (ANIK) Q3 2026 Earnings Call Highlights: Revenue Growth and Margin Gains ... (opens in a new tab) GuruFocus.com · 06 Nov 2026 21:17
- Anika Therapeutics, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 06 Nov 2026 17:49
- Anika Therapeutics (ANIK) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 06 Nov 2026 17:28
- What Anika Therapeutics (ANIK) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 06 Nov 2026 16:14
- Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 06 Nov 2026 13:04
- Anika Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 06 Nov 2026 12:33
- Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates (opens in a new tab) Zacks · 06 Nov 2026 12:25
- Anika: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 06 Nov 2026 12:22
- Anika Reports Third Quarter 2026 Financial Results (opens in a new tab) 06 Nov 2026 12:05
- Anika Therapeutics Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 06 Nov 2026 10:13
- Anika Therapeutics Raises FY2026 Sales Guidance from $118.460M-$124.101M to $119.588M-$124.101M vs $121.639M Est (opens in a new tab) Benzinga · 06 Nov 2026 08:06
- Anika Therapeutics Q3 Adj. EPS $0.29 Beats $0.06 Estimate, Sales $30.594M Beat $29.436M Estimate (opens in a new tab) Benzinga · 06 Nov 2026 08:06
- Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year? (opens in a new tab) Zacks · 25 Sep 2026 13:40
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 19.33 USD
- Market cap
- 194.9M
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 0.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 20.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 12.3 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- The last full year was a loss
- Revenue has fallen two years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | 15.32× | Fair | 14.89× |
| Price / book | 1.42× | Good | 3.81× |
| Price / sales | 1.58× | Good | 3.19× |
| EV / EBITDA | 31.7× | Weak | 12.63× |
| Free cash flow yield | 4.6% | Fair | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 63.4% | Good | 58.6% |
| Operating margin | -1.9% | Weak | 7.8% |
| Net margin | -1.4% | Weak | 2.8% |
| Return on equity | -0.2% | Weak | 5.7% |
| Return on assets | 0% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | -0.3% | Weak | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.19× | Good | 0.48× |
| Net debt / EBITDA | -3.39× | Good | 1.6× |
| Current ratio | 3.86× | Good | 2.39× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow ANIK and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.